Ahead of a meeting to discuss the potential approval of the COVID-19 vaccine from Moderna (NSDQ:MRNA), FDA data says the candidate is safe and effective.
Cambridge, Mass.-based Moderna filed for emergency use authorization in November, having conducted a Phase 3 study, known as the COVE study, that enrolled more than 30,000 U.S. participants, with 196 confirmed cases of COVID-19. Data analysis indicated a vaccine efficacy of 94.1%. All of the 30 severe cases in the study involved people in the placebo group; none of the severe cases received Moderna’s mRNA-1273 vaccine.
Get the full story at our sister site, Drug Discovery & Development.